Case 1主要說明golf彈出原因是因為入射角和速度問題. By: DAVIDCHOI1224 … Continue reading →

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinsons disease treatment will boost market despite patent cliff and Neurodegenerative Diseases Pipeline Review, H1 2013 are new research reports available at ReportsnReports.com store. Dallas, Texas (PRWEB) March 27, 2013 Scope Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=229830. Reasons to Buy Neurodegenerative Diseases Pipeline Review, H1 2013 (http://www.reportsnreports.com/reports/228409-neurodegenerative-diseases-pipeline-review-h1-2013.html) provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neurodegenerative Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurodegenerative Diseases. Neurodegenerative Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, and investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope Reasons to buy Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=228409. Continued here: Neurodegenerative Diseases Market: Analysis & Forecast 2018 in News Research Report at … Continue reading →

A local group is increasing its outreach starting next month to better educate people on the effects of Parkinson's disease. The Ashland Parkinson's Support Group will have two displays set up at the community center and the public library in April for Parkinson's Awareness Month. "We want to share that this is a serious disease that needs energy put into it to find a cause and a cure," said Martha Budding, the group's coordinator. The displays will include posters, fliers and facts about Parkinson's, a degenerative movement disorder. According to the Parkinson's Disease Foundation, as many as 60,000 Americans are diagnosed with Parkinson's annually. Founded a year and a half ago, the Parkinson's Support Group meets once a month at the community center. Speakers present different Parkinson's-related topics, such as treatment and resources. As many as 20 people attend the monthly presentations, and the group also hosts two exercise programs a week for people with Parkinson's. "We are beginning to see the benefits of the exercises and the topics we have," Budding said. "We are learning more and we are more empowered than we were before." Local resident Malcolm Smart is putting the library display together, which Library Director Paula … Continue reading →

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinsons disease. The data show that MANF protects the integrity of dopamine producing neurites in the striatum. Our scientists are excited by this data, which not only demonstrates the efficacy of MANF, but its superiority to GDNF, as well, said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. Based on this study, we believe MANF plays a role in maintaining brain connectivity, specifically the dopaminergic system of the basal ganglia network, which reinforces the potential of MANF as a disease-modifying treatment for Parkinsons. In the neuroprotection study, MANF was delivered into the substantia nigra shortly before injection of the toxin 6-OHDA into the striatum. Four weeks later the animals were sacrificed and the density of dopaminergic neuron projections in the striatum was determined. The protection of neuron health, as measured by the density of neurite terminals, was evident in all three areas of the striatum examined. The effects of a single MANF treatment were evident after four … Continue reading →

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-2018---New-product-entries-in-both-niche-and-broader-Parkinson's-disease-treatment-will-boost-market-despite-patent-cliff.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff Summary - The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan. - Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations. - Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan. - Key market drivers and barriers - The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total … Continue reading →

LONDON, March 26 (Reuters) - British biotech Phytopharm gave up its search for a treatment for Parkinson's Disease using a drug derived from subtropical plants on Tuesday and said it was looking to sell the business. A month after the medicine, Cogane, failed in a clinical trial, Phytopharm (LSE: PYM.L - news) said it would not commit any more money to further research and development and would cut staff. The company said it had held exploratory merger talks with a number of parties. Cogane's failure - the latest in a line that include Renovo, Minster and Antisoma - highlighted the all-or-nothing bet that small biotechs need to make to develop and launch drugs on their own. Phytopharm suffered earlier setbacks. It abandoned research aiming to commercialise a drug for the management of obesity derived from a southern African cactus called Hoodia gordonii three years ago, to focus its efforts on Cogane instead. It raised 24 million pounds ($36 million)from investors to fund research into Cogane. The British company had hoped its compounds had the potential to be a new class of therapy for neurodegenerative diseases, such as Parkinson's and motor neurone disease. Early trials indicated that Cogane could ease the … Continue reading →